David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
The purpose of this study is to analyze the problematic impact of technology on American health care. Although the pharmaceutical industry's use of technology has produced beneficial results, at times the industry seems to overlook the unintended consequences involved. This study also examines the pharmaceutical industry's attempts to influence the physician's prescribing decisions as well as the patient's desire to get well as soon as possible. It analyzes the FDA's role in approving drugs, in monitoring the post-approval process, and in overseeing the industry's technological excesses. While the industry has the admirable goal of trying to relieve or eradicate illness, a few firms regularly engage in questionable behavior as they strive to increase their profitability. In addition to using ethically suspect marketing techniques, some firms suppress unfavorable research. In sum, it is clear that the drug industry needs to engage in deeper ethical reflection. ^
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library||
References found in this work BETA
No references found.
Citations of this work BETA
No citations found.
Similar books and articles
John T. Fielding (1999). Dangerous Medicine: The Pharmaceutical Industry's Questionable Ethical Practices. Dissertation, Salve Regina University
Shaili Jain (2007). Understanding Physician-Pharmaceutical Industry Interactions. Cambridge University Press.
Richard T. de George (2005). Intellectual Property and Pharmaceutical Drugs. Business Ethics Quarterly 15 (4):549-575.
Edward R. Balotsky (2009). Where Strategy and Ethics Converge: Pharmaceutical Industry Pricing Policy for Medicare Part D Beneficiaries. [REVIEW] Journal of Business Ethics 84 (1):75 - 88.
Marc A. Rodwin (2011). Reforming Pharmaceutical Industry-Physician Financial Relationships: Lessons From the United States, France, and Japan. Journal of Law, Medicine & Ethics 39 (4):662-670.
Steven C. Schachter (ed.) (2008). Managing Relationships with Industry: A Physician's Compliance Manual. Elsevier.
Włodzimierz Kubiak (2005). Medicine and Pharmacy — Facts and Myths About the Development of an Innovative Pharmaceutical Industry in Poland. Science and Engineering Ethics 11 (1):41-51.
Joao Calinas-Correia (2013). Big Pharma: A Story of Success in a Market Economy. [REVIEW] Medicine, Health Care and Philosophy 16 (2):305-309.
James Weber & Jennifer J. Griffin (2005). Industry Social Standings. Proceedings of the International Association for Business and Society 16:190-195.
Sean Ekins & Richard J. McGowan (2002). Postgraduate Education and the Changing Interaction with the Pharmaceutical Industry: A Cross-Cultural Perspective. [REVIEW] Foundations of Science 7 (4):413-424.
Jürgen Poesche (1998). Business Ethics in the Choice of New Technology in the Kraft Pulping Industry. Journal of Business Ethics 17 (5):471 - 489.
Ya-Hui Hsu, Wenchang Fang & Yuanchung Lee (2009). Ethically Questionable Behavior in Sales Representatives — An Example From the Taiwanese Pharmaceutical Industry. Journal of Business Ethics 88 (1):155 - 166.
Denis Gordon Arnold (ed.) (2009). Ethics and the Business of Biomedicine. Cambridge University Press.
Eva Turner (2001). The Case for Responsibility of the IT Industry to Promote Equality for Women in Computing. Science and Engineering Ethics 7 (2):247-260.
Added to index2012-03-02
Total downloads2 ( #511,927 of 1,699,800 )
Recent downloads (6 months)2 ( #269,935 of 1,699,800 )
How can I increase my downloads?